-transparent.png){kind=logo}
Liver transplantation or the surgical construction of portacaval shunts may radically alter an individual's debrisoquine hydroxylation capacity. Good clinical management should encompass a full awareness of such changing needs and problems in patients who undergo hepatic surgery.
Related Publications
S C Mitchell, and
R R Shah, and
D G Clements, and
R L Smith
February 1981,
Clinical pharmacology and therapeutics,
S C Mitchell, and
R R Shah, and
D G Clements, and
R L Smith
June 2004,
British journal of clinical pharmacology,
S C Mitchell, and
R R Shah, and
D G Clements, and
R L Smith
August 1983,
Life sciences,
S C Mitchell, and
R R Shah, and
D G Clements, and
R L Smith
October 1977,
Lancet (London, England),
S C Mitchell, and
R R Shah, and
D G Clements, and
R L Smith
August 1992,
Acta neurologica Scandinavica,
S C Mitchell, and
R R Shah, and
D G Clements, and
R L Smith
December 1990,
Lancet (London, England),
S C Mitchell, and
R R Shah, and
D G Clements, and
R L Smith
March 1989,
Lancet (London, England),
S C Mitchell, and
R R Shah, and
D G Clements, and
R L Smith
January 1992,
Psychopharmacology bulletin,
S C Mitchell, and
R R Shah, and
D G Clements, and
R L Smith
January 1995,
European journal of clinical pharmacology,
S C Mitchell, and
R R Shah, and
D G Clements, and
R L Smith
November 1990,
Diabetes research (Edinburgh, Scotland),
